Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer

ABSTRACT IMscin001 is a two‐part dose‐finding (Phase Ib) and ‐confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC). The objectives...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Phyllis Chan, Stephanie N. Liu, Nathalie Gosselin, Zacharie Sauve, Mathilde Marchand, Alyse Lin, Luis Herraez‐Baranda, James Zanghi, Esther Shearer‐Kang, Xiaoyan Liu, Benjamin Wu, Pascal Chanu
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2025-04-01
Ráidu:	CPT: Pharmacometrics & Systems Pharmacology
Liŋkkat:	https://doi.org/10.1002/psp4.13310
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!